USABiotech & Genomic Medicine▲
Satellos reports six-month TRAILHEAD data showing reduced muscle fat fraction and improved effort in DMD adults treated with SAT-3247
Satellos Bioscience announced six-month interim data from its TRAILHEAD study showing that its investigational drug SAT-3247 reduced muscle fat fraction and increased effort in four adults with Duchenne muscular dystrophy. All four participants showed a decline in fat fraction as measured by MRI, with a mean improvement of 3.7% from 49.7% at baseline to 46.0% at month 6, suggesting improved muscle composition. All four participants also showed an increase in TE99C, a measure of maximum effort in upper limbs, with a mean improvement of approximately 34% from a baseline of 16.1 joules per kilogram to 21.6 joules per kilogram at month 6. Handgrip strength nearly doubled during the prior 28-day CL-101 study and was maintained through month 6 of TRAILHEAD. Mean creatine kinase, a biomarker of muscle damage, declined 38% from baseline through month 6. The safety profile of SAT-3247 remained favorable and consistent with previously reported results.